| Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis P Kawalec, P Holko, P Moćko, A Pilc Rheumatology international 38 (2), 189-201., 2018 | 70 | 2018 |
| Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis P Kawalec, P Holko, M Gowin, A Pilc Archives of Medical Science 14 (5), 1125–1136, 2018 | 65 | 2018 |
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis P Kawalec, A Paszulewicz, P Holko, A Pilc ARCHIVES OF MEDICAL SCIENCE 8 (5), 767-775, 2012 | 62 | 2012 |
| The Effect of Vanadyl Sulphate (VOSO4) on autocrine growth of human epithelial cancer cell lines P Holko, J Ligęza, J Kisielewska, AM Kordowiak, A Klein Pol J Pathol 59 (1), 3-8, 2008 | 49 | 2008 |
| Sodium orthovanadate affects growth of some human epithelial cancer cells (A549, HTB44, DU145) A Klein, P Holko, J Ligeza, AM Kordowiak Folia biologica 56 (3-4), 115-121, 2008 | 45 | 2008 |
| Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer P Holko, P Kawalec Expert Review of Anticancer Therapy 14 (1), 63-73, 2014 | 37 | 2014 |
| Health-related quality of life impairment and indirect cost of Crohn’s disease: a self-report study in Poland P Holko, P Kawalec, M Mossakowska, A Pilc PloS one 11 (12), e0168586, 2016 | 32 | 2016 |
| Comparative safety of high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis: A systematic review and network meta-analysis K Śladowska, P Kawalec, P Holko, O Osiecka Neurological sciences 43 (9), 5479-5500, 2022 | 26 | 2022 |
| Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012–2014: an analysis of nationwide databases P Holko, P Kawalec, E Stawowczyk European journal of gastroenterology & hepatology 30 (4), 456-464, 2018 | 23 | 2018 |
| Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist P Holko, P Kawalec, A Pilc PharmacoEconomics, 2018 | 22 | 2018 |
| Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study P Holko, P Kawalec, M Mossakowska European Journal of Gastroenterology & Hepatology 30 (2), 174-180, 2018 | 22 | 2018 |
| Vanadium derivatives as compounds of high biological significance. Part I. Antidiabetic activity AM Kordowiak, P Holko Postepy Biologii Komorki 36 (3), 361-376, 2009 | 21* | 2009 |
| Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting P Kawalec, P Holko, E Stawowczyk, Ł Borowiec, KJ Filipiak Polish Heart Journal (Kardiologia Polska) 73 (9), 768-780, 2015 | 17 | 2015 |
| Cost-utility analysis of Ruconest® (conestat alfa) compared to Berinert® P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in … P Kawalec, P Holko, A Paszulewicz Postepy Dermatologii i Alergologii 30 (3), 152-158, 2013 | 17 | 2013 |
| Indirect Costs of Inflammatory Bowel Diseases: A Comparison of Patient-Reported Outcomes Across 12 European Countries P Holko, P Kawalec, M Sajak-Szczerba, L Avedano, M Mossakowska Inflammatory Bowel Diseases, 2022 | 12 | 2022 |
| Impact of biologic treatment of Crohn’s disease on the rate of surgeries and other healthcare resources: an analysis of a nationwide database from Poland P Holko, P Kawalec, A Pilc Frontiers in pharmacology 9, 621, 2018 | 12 | 2018 |
| Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase … P Kawalec, P Holko, A Paszulewicz, K Obtułowicz Pneumonol Alergol Pol 81 (2), 95-104, 2013 | 11 | 2013 |
| Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis K Krawczyk, K Śladowska, P Holko, P Kawalec Frontiers in pharmacology 14, 1223929, 2023 | 9 | 2023 |
| Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS P Holko, P Kawalec Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 79-88, 2011 | 7 | 2011 |
| Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries P Holko, P Kawalec, M Sajak-Szczerba, L Avedano, M Mossakowska The European Journal of Health Economics 24 (7), 1073-1083, 2023 | 5 | 2023 |
Paweł KawalecInstytut Zdrowia Publicznego Collegium Medicum UJ Verifisert e-postadresse på uj.edu.pl
